



Form PTO-1449 (modified)

Atty. Docket No.
FHCC:010USSerial No.
10/648,978

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

Applicant
Thomas Spies
Veronika SpiesFiling Date:
August 27, 2003Group:
1644

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
MB	B1	WO 92/17198	3/27/92	PCT			
MB	B2	WO 01/71005	3/26/01	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
MB	C1	Azuma <i>et al.</i> , "CD28 T lymphocytes-antigenic and functional properties," <i>J. Immunol.</i> , 150(4):1147-1159, 1993.
	C2	Bauer <i>et al.</i> , "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA," <i>Science</i> , 285(5428):727-729, 1999.
	C3	Billadeau <i>et al.</i> , "NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway," <i>Nat. Immunol.</i> , 4(6):557-564, 2003.
	C4	Chalupny <i>et al.</i> , "ULBP4 is a novel ligand for human NKG2D," <i>Biochem. Biophys. Res. Commun.</i> , 305:129-135, 2003.
	C5	Cosman <i>et al.</i> , "ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor," <i>Immunity</i> , 14:123-133, 2001.
	C6	Das <i>et al.</i> , "MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function," <i>Immunity</i> , 15:83-93, 2001.
	C7	Diefenbach <i>et al.</i> , "Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages," <i>Nat. Immunol.</i> , 1:119-126, 2000.
MB	C8	Diefenbach <i>et al.</i> , "Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity," <i>Nature</i> , 413:165-171, 2001.

25348137.1

EXAMINER:

DATE CONSIDERED:

5/31/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

FHCC:010US

10/648,978

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

August 27, 2003

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
MB	C9	Groh <i>et al.</i> , "Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium," <i>Proc. Natl. Acad. Sci., USA</i> , 93:12445-12450, 1996.
	C10	Groh <i>et al.</i> , "Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells," <i>Nature Immunology</i> , 2(3):255-260, 2001.
	C11	Groh <i>et al.</i> , "Recognition of stress-induced MHC molecules by intestinal epithelial $\gamma\delta$ T cells," <i>Science</i> , 279:1737-1740, 1998.
	C12	Groh <i>et al.</i> , "Broad tumor-associated expression and recognition by tumor-derived $\gamma\delta$ T cells of MICA and MICB," <i>Proc. Natl. Acad. Sci., USA</i> , 96:6879-6884, 1999.
	C13	Groh <i>et al.</i> , "Tumour-derived soluble MIC ligand impair expression of NKG2D and T-cell activation," <i>Nature</i> , 419:734-738, 2002.
	C14	Houchins <i>et al.</i> , "DNA sequence analysis of NKG2, a family of related cDNA clones encoding typeII integral membrane proteins on human natural killer cells," <i>J. Exp. Med.</i> , 173:1017-1020, 1991.
	C15	Kubin <i>et al.</i> , "ULBP1, 2, 3: novel MHU class I-related molecules that bind to human cytomegalocirus glycoprotein UL16, activate NK cells," <i>European Journal of Immunology</i> , 31(5):1428-1437, 2001.
	C16	Li <i>et al.</i> , "Crystal structure of the MHC class I homolog MIC-A, a $\gamma\delta$ T cell ligand," <i>Immunity</i> , 10:577-584, 1999.
	C17	Pende <i>et al.</i> , "Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin," <i>Eur. J. Immunol.</i> , 31:1076-1086, 2001.
	C18	Posnett <i>et al.</i> , "Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones," <i>Int. Immunol.</i> , 11:229-241, 1999.
	C19	Roberts <i>et al.</i> , "NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment," <i>J. Immunol.</i> , 167:5527-5530, 2001.
MB	C20	Salih <i>et al.</i> , "Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia," 102(4):1389-96, <i>Blood</i> , 2003.

25348137.1


EXAMINER:

DATE CONSIDERED:

5/31/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

FHCC:010US

Serial No.

10/648,978

Applicant

Thomas Spies

Veronika Spies

Filing Date:

August 27, 2003

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
M/S	C21	Sutherland <i>et al.</i> , "UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells," <i>J. Immunol.</i> , 168:671-679, 2002.
M/S	C22	Wu <i>et al.</i> , "An activating immunoreceptor complex formed by NKG2D and DAP 10," <i>Science</i> , 285:730-732, 1999

25348137.1

EXAMINER:

DATE CONSIDERED:

5/31/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

FHCC:010US

Serial No.

10/648,978

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Thomas Spies

Veronika Spies

Filing Date:

August 27, 2003

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
M/S	C23	Lehner, "Immunopathogenesis of Behçet's disease," Ann Med Interne, 150(6):483-487, 1999.

25558521.1

EXAMINER:

DATE CONSIDERED:

5/31/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)